Switzerland· 62598003

Kombiglyze XR

A metformin and saxagliptin product containing metformini hydrochloridum, saxagliptinum, registered in Switzerland and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 12 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat B (Swissmedic)ATC A10BD10

Checked against BAG Spezialitätenliste (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHBAG Spezialitätenliste (Switzerland)normalisedKombiglyze XRATCA10BD10REGISTER NO.62598003PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Metformin and saxagliptin is registered in 12 of 19 countries.

Countries holding a registration under ATC A10BD10 (metformin and saxagliptin), each read from that country’s own register.

  • This record: Switzerland, from BAG Spezialitätenliste (Switzerland)
  • 7 of them publish a price we can compare per daily dose

Metformin and saxagliptin · ATC A10BD10

12 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

BAG Spezialitätenliste (Switzerland)
Active substance
metformini hydrochloridum, saxagliptinum
Manufacturer
—
Country
Switzerland (CH)
ATC code
A10BD10
ATC class
Metformin and saxagliptin
Swissmedic category
B
Reimbursed
Yes
Source register
BAG Spezialitätenliste (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680625980036
    196 Stk
    CHF 159.45

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

3 interactions on record for metformin and saxagliptin.

Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Metformin and saxagliptin · interactions on record

3 records

3 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
Mechanism and what to do, in the interaction check
Interaction register. Grades as the source publishes them.

Same medicine, other countries

Metformin and saxagliptin in 12 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All metformin and saxagliptin products

Authorised across Europe · EMA

The same active substance is authorised in 5 EEA countries. Names it is sold under:

  • France · Saxagliptine/Metformine Biogaran
  • Iceland · Komboglyze
  • Liechtenstein · Komboglyze
  • Malta · Saxagliptin/Metformin Pharos
  • Norway · Komboglyze

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of BAG Spezialitätenliste (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/dcf3db18-4b98-4102-b52c-7fecbfdffe25
GET /v1/drugs/dcf3db18-4b98-4102-b52c-7fecbfdffe25?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "metformini hydrochloridum 1000 mg + saxagliptinum 2.5 mg",
  "valid_from": "2013-11-01",
  "limitations": "[{\"description\":\"Zur Behandlung von Patienten mit einem Typ 2 Diabetes mellitus, wenn durch Diät und gesteigerte körperliche Aktivität keine ausreichende Kontrolle der Glykämie erreicht wird:<br>\\n- Als Dreifachkombination mit einem Sulfonylharnstoff, wenn mit Metformin und Sulfonylharnstoff (als orale Zweifachkombination und in maximal verträglicher Dosierung) keine ausreichende Kontrolle der Glykämie erreicht wird.<br>\\n- In Kombination mit Insulin, wenn mit den bisherigen oralen Therapien (in maximal verträglicher Dosierung) zusammen mit Diät und vermehrter körperlicher Aktivität keine ausreichende Kontrolle der Glykämie erreicht wird.<br>\\n- Für Patienten, die bereits mit einer freien Kombination von Saxagliptin und Metformin behandelt werden.<br>\\n<br>\",\"costApproval\":null,\"indication\":null,\"isNew\":false,\"limitationCode\":null,\"points\":null,\"priceModel\":null,\"title\":null,\"validFrom\":\"2020-12-01\",\"validTo\":null}]",
  "galenic_form": "Filmtabl 2.5 mg/1000 mg",
  "therapeutic_area": null,
  "sl_inclusion_date": "2013-11-01",
  "self_retention_pct": 10
}

See everything about metformin and saxagliptin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.